Browsing by Author "Rodríguez-Vida, Alejo"

Sort by: Order: Results:

  • Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
    Climent, Miguel Ángel; Álvarez, Carlos; Morales-Barrera, Rafael; Maroto, Pablo; Rodríguez-Vida, Alejo; Méndez-Vidal, María José; García del Muro, Xavier; Puente, Javier; Láinez, Nuria; Vázquez, Sergio; Castellano, Daniel; Gómez Lang, Carmen; Wang, Jing; Di Pietro, Alessandra; Davis, Craig; Sanz Castillo, Belén; Bolós, M. Victoria; Valderrama, Begoña P. (Springer, 2024)
    Purpose: Post hoc analysis of the JAVELIN Bladder 100 trial of avelumab maintenance in locally advanced/metastatic urothelial carcinoma (la/mUC) to determine the interaction by programmed death ligand 1 (PD-L1) status for ...
  • Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer
    Conteduca, Vincenza; Rodríguez-Vida, Alejo; De Giorgi, Ugo (Elsevier, 2019)
    Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is ...
  • SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence
    Hernández Llodrà, Silvia; Segalés Tañà, Laura, 1994-; Juanpere, Nuria; Lorenzo Perez, Marta; Salido Galeote, Marta; Nonell Mazelon, Lara, 1972-; López Martos, David; Rodríguez-Vida, Alejo; Bellmunt Molins, Joaquim, 1959-; Fumadó Ciutat, Lluis; Cecchini Rosell, Lluís; Lloreta, Josep, 1958- (Wiley, 2021)
    Background: In the non-ETS fusion of prostate cancer (PCa) pathway, SPOP mutations emerge as a distinct oncogenic driver subclass. Both SPOP downregulation and mutation can lead to SPOP target stabilization promoting ...
  • Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
    Jiménez, Natalia; Reig, Òscar; Marín-Aguilera, Mercedes; Aversa, Caterina; Ferrer-Mileo, Laura; Font, Albert; Rodríguez-Vida, Alejo; Climent, Miguel Ángel; Cros, Sara; Chirivella, Isabel; Doménech, Montserrat; Figols, Mariona; González-Billalabeitia, Enrique; Jiménez Peralta, Daniel; Rodríguez-Carunchio, Leonardo; García-Esteve, Samuel; García de Herreros, Marta; Ribal, Maria J.; Prat, Aleix; Mellado, Begoña (MDPI, 2022)
    Background: androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking